Drug Trial Radar · NCT06994936
An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector
Last checked: Nov 19, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Jun 5, 2025
Primary completion
Nov 1, 2025
Study completion Nov 1, 2025
Sponsor
- Lead sponsor
- MoonLake Immunotherapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- May 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a study to confirm the relative bioequivalence of sonelokimab administered subcutaneously via a prefilled syringe (PFS) or an autoinjector (AI) in healthy adult volunteers
Conditions
- Relative Bioequivalence
Interventions
SonelokimabDrug
sonelokimab 120 mg administered subcutaneously via a PFS
SonelokimabDrug
sonelokimab 120 mg administered subcutaneously via an AI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of pharmacokinetics (PK) of an AI versus PFS administered single dose of sonelokimabTime frame: 64 days
- Comparison of pharmacokinetics (PK) of an AI versus PFS administered single dose of sonelokimabTime frame: 64 days
- Comparison of pharmacokinetics (PK) of an AI versus PFS administered single dose of sonelokimabTime frame: 64 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.